Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The decision is based on a re-evaluation of all available clinical data on olmutinib and recent treatment advances made in the treatment of EGFR…
Hanmi shares fell 18% on the Korea Exchange to their lowest level since October 2015, reflecting investor disappointment after Boehringer cited 're-evaluation…
Hanmi conceded the value as a novel drug had declined significantly relative to remaining R&D costs after both Boehringer and Zai Lab walked away and Tagrisso…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Boehringer Ingelheim terminated its July 2015 license/collaboration with Hanmi Pharmaceutical for olmutinib (HM61713), a 3rd-generation EGFR inhibitor for T790M-mutant NSCLC. Original deal: $50M upfront plus up to $680M in milestones plus tiered double-digit royalties (~$730M total). Termination triggered by Korean safety alerts (toxic epidermal necrolysis cases including one fatal SJS) and competitive pressure from AstraZeneca's Tagrisso. Hanmi retained $65M already received.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hanmi Pharmaceutical Co. Ltd. / Boehringer Ingelheim GmbH (this deal) | 2016 | $730M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2016 deals · Oncology deals